In March of 2024, AstraZeneca reported that it had received more than $13 billion in marketing from the drugmaker for its anti-cholesterol drug Crestor. That figure included marketing of the generic version, which is already the blockbuster anti-cholesterol drug Crestor. In March, the company announced that it was considering launching generic Crestor under the brand name "Crestor," though the company is not disclosing the details. The drug, which is the generic version of Crestor, is prescribed to adults with a history of coronary artery disease, a type of heart disease that can cause narrowing of the arteries that supply blood to the heart and lungs. Crestor's patent covering a significant portion of the U. S. market for the drug, covering around 30 percent of the U. market, was set to expire in December 2025.
On March 14, the FDA released a safety warning for the Crestor medicine, warning that patients taking the drug should not take the drug or stop taking it immediately or for extended periods. The drug's label said that statins (also known as anti-inflammatory medications) could cause heart attacks and strokes in people who have heart disease and those who have had previous heart attacks. Statins are also known to increase the risk of certain types of cancer, such as colon cancer, in people who have high blood cholesterol levels.
AstraZeneca's Crestor, which it acquired in May of 2003, is currently the No. 1 selling cholesterol drug. The drug is one of the most commonly prescribed brand-name cholesterol-lowering drugs in the U. and is the No. 2 selling cholesterol-lowering drug in the U. AstraZeneca acquired the rights to Crestor in July of 2014. The company's name is derived from the brand name Crestor, which is used in prescription medicine.
The drug company has a $25 billion global sales budget, which includes the company's $2.8 billion in sales of its generic Crestor. The company has $6.3 billion in net income from the sale of its Crestor drug.
Last year, the company received an FDA warning that Crestor was "a potentially serious safety hazard" because it could lead to heart attacks and strokes. The warning was based on a study that showed a small risk of these serious side effects in patients who took a statin. The FDA also said that Crestor had a low incidence of serious cardiovascular events, including heart attack, stroke and death in patients taking statins.
On March 24, the company announced that it was considering launching generic Crestor. The company has yet to disclose the specifics of the launch of the drug. AstraZeneca will continue to sell the drug without disclosing the cost of the generic version of Crestor, but the company has said it will sell the drug under the brand name "Crestor." The company's share price has been at a $2.35 apiece since it was acquired by Teva Pharmaceuticals last year. It has $13.50 to $13.50 in net income from sales of the generic Crestor, while $10.10 to $10.15 in sales of the brand-name version of the drug.
The company has not disclosed the specifics of the launch of the generic version of Crestor.
Crestor is the branded version of a statin approved by the FDA in early 2003 and a second-generation drug. The brand name is based on Crestor's name. The company did not disclose the cost of the generic version of Crestor, although the company said that it was considering doing so.
The company has a $9.85 billion U. sales budget, with $6.6 billion of that coming from sales of the brand-name version of the drug.
Rosuvastatin (Crestor) is a cholesterol-lowering drug. It is mainly used for patients who are at a high risk of developing heart disease, such as those who have high blood pressure and are at a high risk for coronary heart disease. However, it is not known how much it will affect people’s cholesterol levels and thus, how long it may affect them.
Rosuvastatin is available as an oral tablet and oral suspension. Rosuvastatin is widely used in the treatment of hypercholesterolemia (high cholesterol levels). However, the effects of rosuvastatin on lipid parameters have not been studied.
In a retrospective study, rosuvastatin was used to treat hypercholesterolemia in patients with primary hypercholesterolemia (high cholesterol levels) when they are treated with statins.
The study reported on the effect of rosuvastatin on lipid parameters and lipid-related adverse events (AEs) in patients with primary hypercholesterolemia.
Statins are a group of medicines that are used to treat many conditions. Rosuvastatin is the most widely used statin, and it is one of the main drugs used for statin treatment in the United States. It belongs to the class of drugs called HMG CoA reductase inhibitors, which prevent the breakdown of cholesterol in the liver by preventing its production. Rosuvastatin is also used in combination with diet and exercise in patients who have cardiovascular disease. In addition, it is also used for the treatment of certain types of hypercholesterolemia, such as pre-clinical atherosclerosis and patients who are at risk of developing this condition.
Statins are considered the first-line drug for treating hypercholesterolemia. Rosuvastatin is considered one of the best drugs for the treatment of high cholesterol in the first-line statin therapy group. The main advantage of statins is that they are relatively inexpensive and are usually prescribed in combination with a lower dose of the drug, which is the most effective form of treatment for the treatment of patients with high cholesterol.
Statins are available as the brand name Rosuvastatin. The generic versions are available under the name Crestor. Rosuvastatin is also available as the brand name Lipitor. The FDA has approved rosuvastatin for the treatment of:
Crestor is considered one of the best drugs for the treatment of high cholesterol in the first-line therapy group. It is also used in combination with diet and exercise in patients who have cardiovascular disease. It is considered one of the best drugs for the treatment of hypercholesterolemia. The main advantage of Crestor is that it is considered a safe drug. Rosuvastatin is considered a good choice for treating hypercholesterolemia in patients with primary hypercholesterolemia.
Rosuvastatin is considered one of the best drugs for the treatment of high cholesterol. It is also one of the best drugs for the treatment of hypercholesterolemia in the first-line therapy group. The main advantage of statins is that they are relatively inexpensive and are usually prescribed in combination with a lower dose of the drug, which is the most effective form of treatment for the treatment of hypercholesterolemia.
In addition, statins are considered to be very effective in preventing atherosclerosis. Statins have a very long half-life, and the main advantage of statins is that they are relatively fast-acting. They are available in both oral and injectable forms.
In the first-line therapy group, rosuvastatin was shown to have a moderate effect on the heart rate. A small effect of rosuvastatin on the heart rate was seen in both short-term (1-year) and long-term (6-month) studies. The most common finding of the study was that the effect of rosuvastatin on heart rate was not statistically significant between different statin treatment groups.
In the treatment group, rosuvastatin was also shown to have a positive effect on heart rate.
Here are a few resources that may help you save on Crestor:
A. Coupons & Patient Assistance:You may be able to receive a savings or copay for Crestor at any time by calling our customer service number 1 (877-477-3377) or calling 1 (1-800- Extend-Filling).
B. Savings Programs:Some savings programs may provide you with a discount on Crestor, so make sure to talk to your doctor first to see if you qualify for a savings or copay.
C. Patient Assistance:You may be able to receive a copay for Crestor from your doctor, or from a pharmacy benefit manager (such as RxWise).
D.Some savings programs may provide you with a copay for Crestor, or from your employer. To get a discount, you can fill out a form on our website with your prescription.
Copay Cards:You may be able to pay for Crestor on a copay card when you complete a refill of your prescription.
Some savings programs may provide you with a discount on Crestor, or from your employer.
Crestor is a lipase inhibitor. It contains the active ingredient rosuvastatin, which belongs to the class of medications known as statins. It works by preventing the production of cholesterol, the main component of our bodies.
When taken as a tablet or capsule, Crestor can help to prevent high cholesterol levels from forming, which can lead to a range of health problems.
One of the most common side effects of Crestor is swelling, especially in the hands and feet, which can cause difficulty in walking and even losing weight. This can cause discomfort, and it can lead to muscle weakness and shortness of breath.
Another side effect of Crestor is gastrointestinal discomfort. This can include vomiting, stomach cramps, diarrhoea, and abdominal pain.
If you experience any of these symptoms, it is recommended that you stop taking Crestor and consult a doctor. Stopping Crestor without any consultation is not recommended, as it can cause serious health issues.
Crestor can be dangerous if used without proper medical advice. It can cause serious health problems if you are taking a higher dosage of a statin. Symptoms of a statin include muscle aches and pains, fast or irregular heartbeat, and muscle aches.
Crestor side effects can include:
It is advised to check the side effects before starting Crestor. These side effects may include:
If you experience any of these side effects, it is recommended that you stop taking Crestor and consult a doctor. Stopping Crestor without any consultation is not recommended, as it can cause serious health problems.
It is recommended to check the side effects before starting Crestor.
If you experience any of these side effects, they are not recommended. It is important to speak to a doctor before starting any new medication.
It is advised to speak to a doctor before starting Crestor.
Product name:CRESTOR 40mg
Company name:
DIN:02242404
Status:Marketed
Status date:2021-08-26
| Active ingredient(s) | Strength |
|---|---|
| CEITRAZOLE | 40mg |
Click on a resource to visit a page with more information. You may be taken away from this page to a different Government of Canada website.
For consumers| Resource | Description |
|---|---|
The Product Monograph is a scientific document that describes the properties, claims, indications and conditions of use of the product and contains any other information that may be required for optimal, safe and effective use. The Product Monograph includes three sections:
| |
Side effects are troublesome symptoms or feelings that you may not expect that show up when you are taking a medicine. All suspected side effects should be reported, especially those that are:
|
Section C.01.020.1 of the Food and Drug Regulations and section 62 of the Medical Devices Regulations, require hospitals to report to Health Canada all serious adverse drug reactions (ADRs) and medical device incidents (MDIs) within 30 days of being documented within the hospital. This regulatory requirement only applies to hospitals. |
| After Health Canada completes the regulatory review process for a product, the clinical information included in a submission is made publicly available for non-commercial purposes. |
Stade de France Pharmacy